Kane Biotech to Release Second Quarter 2024 Financial Results on August 29, 2024 – Conference Call to Follow
August 22, 2024 16:30 ET
|
Kane Biotech Inc.
WINNIPEG, Manitoba, Aug. 22, 2024 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX- V:KNE; OTCQB:KNBIF) (“Kane Biotech”) will announce its second quarter 2024 financial results after market close on...
Kane Biotech Announces Distribution Agreement with Razan Medical Trading for revyve™ Antimicrobial Wound Gel
August 22, 2024 08:30 ET
|
Kane Biotech Inc.
WINNIPEG, Manitoba, Aug. 22, 2024 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX- V:KNE; OTCQB:KNBIF) (the “Company” or “Kane Biotech”) today announces that it has signed a three year distribution...
Kane Biotech Receives Funding Support to Expand the revyve™ Antimicrobial Wound Gel Family
August 13, 2024 08:30 ET
|
Kane Biotech Inc.
WINNIPEG, Manitoba, Aug. 13, 2024 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX- V:KNE; OTCQB:KNBIF) (“Kane Biotech”, “Kane” or the “Company”) announces that it is receiving advisory services and up to...
Kane Biotech Receives FDA Approval to Increase Dosage Allowance of its revyve™ Antimicrobial Wound Gel
July 23, 2024 08:30 ET
|
Kane Biotech Inc.
WINNIPEG, Manitoba, July 23, 2024 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX- V:KNE; OTCQB:KNBIF) (“Kane Biotech”, “Kane” or the “Company”) announces that the US Food and Drug Administration (FDA)...
Kane Biotech Receives ISO 13485:2016 MDSAP Quality Certification
July 17, 2024 08:30 ET
|
Kane Biotech Inc.
WINNIPEG, Manitoba, July 17, 2024 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX-V:KNE; OTCQB:KNBIF) (“Kane Biotech” or “Kane”) announces that it has received ISO 13485:2016 Medical Device Single Audit...
Kane Biotech Announces Issuance of Restricted Share Units
July 15, 2024 08:30 ET
|
Kane Biotech Inc.
WINNIPEG, Manitoba, July 15, 2024 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX-V:KNE; OTCQB:KNBIF), (the “Company” or “Kane Biotech”), today announces that it has issued 4,213,133 restricted share...
Kane Biotech Signs Worldwide License Agreement with Omni Bioceutical Innovations Inc.
July 11, 2024 08:30 ET
|
Kane Biotech Inc.
WINNIPEG, Manitoba, July 11, 2024 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX- V:KNE; OTCQB:KNBIF) (“Kane Biotech” or “Kane”) announces that it has signed a worldwide license agreement with...
Kane Biotech Makes First Commercial Sale of revyve™ Antimicrobial Wound Gel to ProgenaCare Global
June 27, 2024 08:30 ET
|
Kane Biotech Inc.
WINNIPEG, Manitoba, June 27, 2024 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX- V:KNE; OTCQB:KNBIF) (“Kane Biotech” or “Kane”) announces that it has made its first commercial-scale sale of...
Kane Biotech Signs Worldwide License Agreement with Montreal-Based I-MED Pharma Inc.
June 25, 2024 08:30 ET
|
Kane Biotech Inc.
WINNIPEG, Manitoba, June 25, 2024 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX- V:KNE; OTCQB:KNBIF) (“Kane Biotech” or “Kane”) announces that it has entered into a worldwide license agreement with...
Kane Biotech Announces First Quarter 2024 Financial Results
May 23, 2024 16:15 ET
|
Kane Biotech Inc.
WINNIPEG, Manitoba, May 23, 2024 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX- V:KNE; OTCQB:KNBIF) (the “Company” or “Kane Biotech”) today announces its first quarter 2024 financial results. The...